February 15, 2017
Bristol-Myers Squibb is to soon roll out its new hepatitis C drug Ximency (daclatasvir + asunaprevir + beclabuvir) in Japan, aiming to regain its lost ground in the genotype 1 market, where it once claimed the lead with the launch...read more